Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 179-185

  Hao, Chuncheng ^a   Wang, Li ^a   Peng, Shaohua ^a   Cao, Mengru ^a   Li, Hongyu ^a   Hu, Jing ^a   Huang, Xiao ^a   Liu, Wei ^a   Zhang, Hui ^a   Wu, Shuhong ^a   Pataer, Apar ^a   Heymach, John V ^a,b   Eterovic, Agda Karina ^a   Zhang, Qingxiu ^a   Shaw, Kenna R ^a   Chen, Ken ^a   Futreal, Andrew ^a   Wang, Michael ^a   Hofstetter, Wayne ^a   Mehran, Reza ^a   Rice, David ^a   Roth, Jack A ^a   Sepesi, Boris ^a   Swisher, Stephen G ^a   Vaporciyan, Ara ^a   Walsh, Garrett L ^a   Johnson, Faye M ^a,b   Fang, Bingliang ^a,b   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarkers; Gene mutations; Lung cancer; Patient derived xenografts; Tumor models

Indexed keywords

ATM PROTEIN; E1A ASSOCIATED P300 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE LKB1; PROTEIN P53; SCATTER FACTOR; TRANSCRIPTION FACTOR RUNX1; VASCULOTROPIN RECEPTOR 2; NITRIC OXIDE DIOXYGENASE; OXYGENASE; TUMOR MARKER;

ADULT; AGED; ALK GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARID1A GENE; ARTICLE; ATM GENE; BAI3 GENE; CLINICAL ARTICLE; CRIPAK GENE; EGFR GENE; EP300 GENE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HGF GENE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MLL3 GENE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; PATIENT DERIVED XENOGRAFT; PDGRRA GENE; PI3KCA GENE; PRIMARY TUMOR; RUNX1 GENE; SETD2 GENE; STK11 GENE; TP53 GENE; TUMOR GENE; TUMOR XENOGRAFT; VERY ELDERLY; ANIMAL; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY; SCID MOUSE; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; MIDDLE AGED; MUTATION; OXYGENASES;

EID: 84920374898     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.024     Document Type: Article

References (58)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64:9-29.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90.
3. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
4. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
5. Hammerman P.S., Hayes D.N., Wilkerson M.D., Schultz N., Bose R., et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525. Cancer Genome Atlas Research Network.
6. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
7. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
8. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13306-13311.
9. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med 2004, 350:2129-2139.
10. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
11. Shepherd F.A., Rodrigues P.J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med 2005, 353:123-132.
12. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
13. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol 2011, 29:2866-2874.
14. Shaw A.T., Kim D.W., Mehra R., Tan D.S., Felip E., Chow L.Q., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med 2014, 370:1189-1197.
15. Davare M.A., Saborowski A., Eide C.A., Tognon C., Smith R.L., Elferich J., et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:19519-19524.
16. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., McDonald N.T., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol 2012, 30:863-870.
17. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J. Natl. Cancer Inst 2009, 101:6-8.
18. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 2001, 84:1424-1431.
19. Voskoglou-Nomikos T., Pater J.L., Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res 2003, 9:4227-4239.
20. Kola I. The state of innovation in drug development. Clin. Pharmacol. Ther 2008, 83:227-230.
21. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov 2011, 10:328-329.
22. Sivanand S., Pena-Llopis S., Zhao H., Kucejova B., Spence P., Pavia-Jimenez A., et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med 2012, 4. 137ra75.
23. John T., Kohler D., Pintilie M., Yanagawa N., Pham N.A., Li M., et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin. Cancer Res 2011, 17:134-141.
24. Rubio-Viqueira B., Jimeno A., Cusatis G., Zhang X., Iacobuzio-Donahue C., Karikari C., et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res 2006, 12:4652-4661.
25. Julien S., Merino-Trigo A., Lacroix L., Pocard M., Goere D., Mariani P., et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res 2012, 18:5314-5328.
26. Dong X., Guan J., English J.C., Flint J., Yee J., Evans K., et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res 2010, 16:1442-1451.
27. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011, 1:508-523.
28. Perez-Soler R., Kemp B., Wu Q.P., Mao L., Gomez J., Zeleniuch-Jacquotte A., et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin. Cancer Res 2000, 6:4932-4938.
29. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., Garrido-Laguna I., De O.E., Rubio-Viqueira B., et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther 2011, 10:1311-1316.
30. Morelli M.P., Calvo E., Ordonez E., Wick M.J., Viqueira B.R., Lopez-Casas P.P., et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J. Clin. Oncol 2012, 30:e45-e48.
31. Fichtner I., Rolff J., Soong R., Hoffmann J., Hammer S., Sommer A., et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res 2008, 14:6456-6468.
32. Kim M.P., Evans D.B., Wang H., Abbruzzese J.L., Fleming J.B., Gallick G.E. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protoc 2009, 4:1670-1680.
33. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760.
34. Li H., Handsaker B., Wysoker A., Fennell T., Ruan J., Homer N., et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009, 25:2078-2079.
35. Koboldt D.C., Zhang Q., Larson D.E., Shen D., McLellan M.D., Lin L., et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012, 22:568-576.
36. Lonigro R.J., Grasso C.S., Robinson D.R., Jing X., Wu Y.M., Cao X., et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 2011, 13:1019-1025.
37. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 2004, 91:355-358.
38. Kumar P., Henikoff S., Ng P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc 2009, 4:1073-1081.
39. Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., et al. A method and server for predicting damaging missense mutations. Nat. Methods 2010, 7:248-249.
40. Gonzalez-Perez A., Lopez-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score. Condel. Am. J. Hum. Genet 2011, 88:440-449.
41. Reva B., Antipin Y., Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011, 39. e118.
42. Liu P., Morrison C., Wang L., Xiong D., Vedell P., Cui P., et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 2012, 33:1270-1276.
43. Ahn J.W., Kim H.S., Yoon J.K., Jang H., Han S.M., Eun S., et al. Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers. Genome Med 2014, 6:18.
44. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
45. Ruault M., Brun M.E., Ventura M., Roizes G., De S.A. MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a chromosome region frequently deleted in myeloid leukaemia. Gene 2002, 284:73-81.
46. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
47. Lee J., Kim D.H., Lee S., Yang Q.H., Lee D.K., Lee S.K., et al. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:8513-8518.
48. Li F., Mao G., Tong D., Huang J., Gu L., Yang W., et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 2013, 153:590-600.
49. Chen C., Liu Y., Rappaport A.R., Kitzing T., Schultz N., Zhao Z., et al. MLL3 is a Haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 2014, 25:652-665.
50. Zhu X., He F., Zeng H., Ling S., Chen A., Wang Y., et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat. Genet 2014, 46:287-293.
51. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.[Erratum appears in N Engl J Med. 2012 Sep 6;367(10):976]. N. Engl. J. Med 2012, 366:883-892.
52. Shedden K., Taylor J.M., Enkemann S.A., Tsao M.S., Yeatman T.J., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med 2008, 14:822-827. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma.
53. Thuerigen O., Schneeweiss A., Toedt G., Warnat P., Hahn M., Kramer H., et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol 2006, 24:1839-1845.
54. Cardnell R.J., Feng Y., Diao L., Fan Y.H., Masrorpour F., Wang J., et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin. Cancer Res 2013, 19:6322-6328.
55. He Y., Zhou Z., Hofstetter W.L., Zhou Y., Hu W., Guo C., et al. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS ONE 2012, 7. e31087.
56. Devaud C., Westwood J.A., John L.B., Flynn J.K., Paquet-Fifield S., Duong C.P., et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol. Ther 2014, 22:18-27.
57. Vahle A.K., Kerem A., Ozturk E., Bankfalvi A., Lang S., Brandau S. Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice - role of toll-like-receptor 4 expressed on host cells. Cancer Lett 2012, 317:199-206.
58. Yoon S., Zhang R., Bucana C., Fidler I. Epigenetic regulation of multidrug-resistance and metastasis-related genes in human lung adenocarcinoma cells growing in ectopic or orthotopic organs of nude-mice. Int. J. Oncol 1995, 7:1261-1267.